E. Coli Nissle 1917 - Suspension for Infection Prophylaxis

Infections Clinical Trial

— RONi  

Official title:

E. Coli Nissle 1917 - Suspension for Infection Prophylaxis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02802059
• Other study ID #: MU 1441
• Secondary ID: 2015-001763-39
• Status: Completed
• Phase: Phase 3
• Start date: October 7, 2015
• Est. completion date: October 12, 2020

Study information

• Verified date: September 2020
• Source: Ardeypharm GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the long term effects of E. coli strain Nissle 1917 (EcN-Suspension) probiotic bacteria administration on the number of both, bacterial and viral infections during the first 24 months of infant's life. Half of study participants will receive EcN-Suspension, while the other half will receive placebo. In an additional non-clinical explorative evaluation will furthermore be investigated whether the early intestinal colonization with E.coli strain Nissle 1917 affects the establishment of the intestinal microbiota.

Description:

In the course of the present trial the participants will be observed during the first 24 months of life, starting right after birth. All newborns meeting all inclusion criteria and non-fulfilling any exclusion criteria will be included into the trial. Each participant of this clinical trial will be randomly allocated to one of the two trial arms, by using the method of randomly permuted blocks. The newborns will be primarily treated during the first three weeks of life and re-treated after 6 and 12 months according to trial interventional plan. Data on the efficacy and safety will be recorded during control visits after first month, 6, 12, 18 and 24 months. A follow-up examination of study participants will be performed two years after the end of the participation in the present trial (i.e. at an age of 48 months), during which each child will be examined for its normal physical and cognitive development (covered by the U8 standardized examination). In addition data on allergic/atopic complaints or symptoms will be recorded. In an additional non-clinical explorative evaluation, it will furthermore be investigated whether the early intestinal colonization with E.coli strain Nissle 1917 affects the establishment of the intestinal microbiota. Therefore stool samples of study participants will be collected at an age of 24 and 48 months. The microbial composition of these samples will be characterized and compared between the two trial arms (EcN vs. placebo).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 567
• Est. completion date: October 12, 2020
• Est. primary completion date: October 12, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A to 120 Hours

Eligibility

Inclusion Criteria:

• Signed informed consent form by the parents
• Age at inclusion: max. 120 hours after birth
• Functionally mature infant
• Gestational age more than 35th week of development
• Mother's intention to breastfeed the participant
• Readiness of the mother to administer no probiotics additionally to the trial medication

Exclusion Criteria:

• Non-fulfilment of the at least one inclusion criteria
• Lack of propensity/compliance of mother
• 5 min APGAR SCORE less than 5
• 10 min APGAR SCORE less than 8
• pH of umbilical cord blood less than 7 (Determination not obligatory, if APGAR SCORES do not indicate that the child may have suffered from a perinatal asphyxia)
• Any perinatal infection required antibiotic treatment
• Birth weight less than 2000 g
• TORCH-infection of the mother
• HIV-infection of the mother
• Any severe medical condition of mother or newborn which in the opinion of the investigator may have a critical impact on the conduct of the study.

Related Conditions & MeSH terms

• Communicable Diseases
• Infection
• Infections

Intervention

Drug:
• EcN-Suspension
Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks). Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day).
• Placebo
Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks). Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day).

Locations

Country	Name	City	State
Germany	Krankenhaus St. Elisabeth & St. Barbara	Halle (Saale)
Germany	Universitätsklinikum Jena - Klinik für Kinder- und Jugendmedizin	Jena
Germany	Klinikum Westbrandenburg	Potsdam
Germany	Klinikum Südstadt Rostock - Abteilung für Neonatologie	Rostock
Poland	Oddzial Kliniczny Noworodków, Wczesniaków z Intensywna Terapia Noworodka wraz z Wyjazdowym Zespolem "N"	Bydgoszcz
Poland	Samodzielny Publiczny Dzieciecy Szpital Kliniczny Oddzial Kliniczny Neonatologiiul	Warsaw

Sponsors (3)

Lead Sponsor	Collaborator
Ardeypharm GmbH	Clinscience Sp. z o.o., ICON plc

Countries where clinical trial is conducted

Germany,  Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of infections	The total number of infections observed for each participant during its individual study participation standardised per month during the first 24 months of life.; An infection is an episode of illness caused by: Acute upper respiratory tract infections; Acute lower respiratory tract infections; Otitis media; Gastroenteritis; Urinary tract infections; The duration of an episode of illness is defined as the time from the appearance of the first symptom of a study relevant infection to the disappearance of the last symptom. Infections that occur concurrently or one after another within a period of 7 days are only counted separately, if they belong to different groups of illness.; All rhinitides that occur in the first year of a child's life are considered for the count of the primary efficacy variable. Rhinitides that occur in the second year will only be included if they were accompanied by fever (body temperature higher than 38.4°C during at least one measure).	during the first 24 months of life
Secondary	Severity of the course of infections considered as primary variables quantified as the "duration of infections"	duration of infection = the number of days with at least one symptom	during the first 24 months of infants' life
Secondary	Severity of the course of infections considered as primary variables quantified as the "number of hospital admissions caused by infections"	number of hospital admissions caused by infections	during the first 24 months of infants' life
Secondary	Severity of the course of infections considered as primary variables quantified as the "mean number of in-hospital spent days due to infections"	mean number of in-hospital spent days due to infections	during the first 24 months of infants' life
Secondary	Severity of the course of infections considered as primary variables quantified as the "number of antibiotic treatments due to infections".	number of antibiotic treatments due to infections	during the first 24 months of infants' life
Secondary	Severity of the course of infections considered as primary variables quantified as the "number of adverse events".	number of adverse events	during the first 24 months of infants' life
Secondary	Severity of the course of infections considered as primary variables quantified as the "tolerance to trial medication".	Tolerance of trial medication will be assessed by the investigator and scored "very good", "good", "moderate", or "poor".	during the first 24 months of infants' life